Sophiris Stops Additional Doses in Topsalysin Prostate Cancer Trial Following Patient Death

Sophiris Bio has halted additional doses in an open-label study of topsalysin in prostate cancer, as it investigates the death of a patient who died on the same day he received a second dose of the drug. “We are extremely saddened by the death of a patient after receiving a second administration of topsalysin,” said Randall Woods, president and CEO of Sophiris. “Understanding the cause of the patient's death is our first priority and essential to determining the potential for re-administration of topsalysin in future clinical trials.”